Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Intravenous immunoglobulin
7 evidence topics · 10 sources
Guideline recommendation in motor CIDP
Immune globulin intravenous versus placebo: adjusted INCAT response through week 24
“117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7; p=0.0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled randomized evidence for intravenous immunoglobulin
“We included nine RCTs with 372 participants (235 male) from Europe, North America, South America, and Israel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg compared with placebo increases the probability of significant improvement in disability within six weeks of the start of treatment (risk ratio (RR) 2.40, 95% confidence interval (CI) 1.72 to 3.36; number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 5; 5 trials, 269 participants; high‐certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to assess the long‐term benefits and harms of IVIg relative to other treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm induction and maintenance study: responder rate
“Patients received one induction dose of Privigen (2 g/kg body weight [bw]) and up to seven maintenance doses (1 g/kg bw) at 3-week intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall responder rate at completion was 60.7% (95% confidence interval [CI]: 42.41%–76.43%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two serious AEs of hemolysis were reported that resolved after discontinuation of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Maintenance dose-ranging study: response by dose
“Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69–88%] in the 1.0 g/kg group, 65% (22/34; CI: 48–79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78–97%) in the 2.0 g/kg group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rescue treatment of relapse after subcutaneous immunoglobulin or placebo
“Overall, 20 patients received IVIG 10% ( n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all patients, median time to functional improvement was 25 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote